586: Gulley JL, Madan RA, Heery CR. Therapeutic vaccines and immunotherapy in
castration-resistant prostate cancer: current progress and clinical applications.
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e166. PubMed
PMID: 23714490.


587: Gulley JL, Leitman SF, Dahut W, Schlom J. Re: interdisciplinary critique of 
sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl
Cancer Inst. 2012 Jul 18;104(14):1106; author reply 1109-12. doi:
10.1093/jnci/djs280. PubMed PMID: 22825555.


588: Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances,
lessons learned, and areas for further research. Clin Cancer Res. 2011 Jun
15;17(12):3884-91. doi: 10.1158/1078-0432.CCR-10-2656. Review. PubMed PMID:
21680544; PubMed Central PMCID: PMC3471147.


589: Gulley JL, Dahut WL. Future directions in tumor immunotherapy: CTLA4
blockade. Nat Clin Pract Oncol. 2007 Mar;4(3):136-7. PubMed PMID: 17327854.